|
|
View Clinical Trial (Medical Research Study)
|
A Phase III Study of Apixaban in Patients With Atrial Fibrillation - NCT00496769-33756A (Clinical Trial 175492)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy175492.aspx
|
** Please review additional "Nearby Studies" on right ----->
This is an archived study that is no longer available, if you
would like to find active studies please
search our studies.
|
|
 |
 |
|
| City: |
|
Clearwater |
|
State:
|
|
FL |
| Zip Code: |
|
33756 |
| Conditions: |
|
Atrial Fibrillation |
| Purpose: |
|
The purpose of this clinical research study is to learn if apixaban is more effective than
Acetylsalicylic Acid (ASA) in preventing strokes associated with subjects who have atrial
fibrillation. The safety of this treatment will also be studied.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Permanent, paroxysmal or persistent atrial fibrillation documented by 12 lead ECG on
the day of screening OR
- If not in atrial fibrillation at screening, atrial fibrillation must be documented in
the 6 months prior to enrollment by 12 lead ECF, or as an episode at least 5 minutes
in duration on a rhythm strip or Holter recording. Pacemaker or ICD electrogram
recordings may be used to document AF but the duration of atrial fibrillation must be
at least 30 minutes if this is the only documentation of AF
- Presence of at least one of the following risk factors for stroke:
- Prior stroke or TIA
- Age ≥ 75 years
- Arterial hypertension on treatment
- Diabetes mellitus
- Heart failure. NYHA Class 2 or greater at time of enrollment
- Left ventricular ejection fraction 35% or less, documented within 6 months of
enrollment
- Documented peripheral arterial disease (previous arterial revascularization,
limb or foot amputation, or current intermittent claudication with ankle-arm
systolic blood pressure ratio < 0.9)
- The patient is not currently receiving vitamin K antagonist therapy for one of
the following reasons:
- Previous vitamin K antagonist therapy has been demonstrated to be
unsuitable and its use has been discontinued (e.g., poor anticoagulant
control, adverse events, need for other treatments that may interact with
VKA, patient unable or unwilling to adhere to dose or INR monitoring
instructions)
- Vitamin K antagonist therapy has not been previously used but would be
expected to be unsuitable (e.g., unlikely to comply with dosing or
monitoring requirement, need for other treatments which may interact with
VKA, unlikely to adhere to restrictions on alcohol, diet or
non-prescription medications, risk of VKA therapy considered to outweigh
the risk of stroke or systemic embolism, patient is unwilling to take VKA).
- Men and women ≥ 50 years of age
Exclusion Criteria:
- Women who are pregnant or breast feeding
- Women of child bearing potential (WOCBP) who are unwilling to meet the study
requirements for pregnancy testing or are unwilling or unable to use an acceptable
method to avoid pregnancy.
- Atrial fibrillation due to reversible causes (e.g., thyrotoxicosis, pericarditis)
- Valvular disease requiring surgery
- Planned atrial fibrillation ablation procedure to be performed within 3 months
- Conditions other than atrial fibrillation that require chronic anticoagulation (e.g.,
prosthetic mechanical heart valve, venous thromboembolism
- Patient with serious bleeding in the last 6 months or at high risk of bleeding. This
includes, but is not limited to:
- Active peptic ulcer disease
- Platelet count < 100,000/mm3 or hemoglobin < 10g/dL
- Recent stroke (within 10 days)
- Documented hemorrhagic tendencies or blood dyscrasias
- Current alcohol or drug abuse, or psychosocial reasons that make study
participation impractical
- Severe co-morbid condition with life expectancy <1 year
- Severe renal insufficiency (creatinine clearance must be calculated in all
patients: any patient with either a serum creatinine > 2.5 mg/dL [221 umol/L] or
a calculated creatinine clearance < 25 ml/min is excluded)
- ALT or AST > 2 times upper limit of normal or a total bilirubin > 1.5 times upper
limit of normal (unless an alternative causative factor [e.g., Gilbert's syndrome] is
identified)
- Allergy or adverse reaction to ASA
- See section 5.5.1 (Prohibited and/or Restricted Treatments) for therapies which are
prohibited at study entry
- Required treatment with a thienopyridine (clopidogrel or ticlopidine; see also
section 5.5.2.1 Acetylsalicylic acid (ASA) and Thienopyridines).
- Prisoners or subjects who are compulsory detained (involuntarily incarcerated)
- Use of an investigational drug or device within the past 30 days or prior
randomization into an apixaban clinical study
- Patients who are compulsorily detained for treatment of either a psychiatric or
physical (e.g., infectious disease) illness |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 1, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|